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LYMPHOCYTES from patients with ma-
lignant diseases can be differentiated
from those of healthy donors or donors
with non-malignant disorders by changes
in the structuredness of cytoplasmic
matrix (SCM) induced by cancer basic
protein (CaBP) and phytohaemagglutinin
(Cercek, Cercek and Franklin, 1974;
Cercek and Cercek, 1974). Cancer basic
protein is recognized by lymphocytes
from all patients with different malignant
diseases and is therefore a nonspecific
" antigen ". The SCM test thus offers
an aid in diagnosing whether a disease
is of a malignant nature or not and in
monitoring the success ofsurgical removal
of malignant tissues (Cercek and Cercek,
1975).
However, lymphocyte responses to
CaBP and PHA do not reveal the type
or site of the tumour. To explore if the
SCM test could be made tumour specific,
we have started a study in which lympho-
cytes from donors with different malignant
disorders and those from healthy donors
are challenged or " baited " with cell
associated, tissue specific antigens. We
found that in the following modification
of the SCM test lymphocytes from donors
with different malignant diseases de-
creased the SCM only when challenged by
specific tumour tissues.
The technique of measurement of the
SCM and the preparation of lymphocytes
forthis test are the same as those described
before (Cercek, Cercek and Ockey, 1973;
Cercek et al., 1974). For the stimulation
or challenge oflymphocytes, histologically
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defined biopsies of tumour or normal
tissues are used, either fresh or after
storage in dry ice or liquid nitrogen.
Before use the frozen pieces of tissue are
slowly thawed at room temperature.
Tissues are well washed in TC medium
199 and also stored in this mediunm until
required. Pieces ofapproximately 4 x 4 x 3
mm size are used for the stimulation.
Aliquots of 0 5-1 ml of lymphocyte
suspensions (approximately 5 x 106 cells/
ml) are incubated with pieces of tumour
or normal tissues for 10-15 min at 37°C.
To achieve frequent contact between
lymphocytes and the tissue, the suspen-
sion is gently mixed 2-3 times during the
incubation time. Aliquots of 0-2 ml of
lymphocyte suspensions are used for the
measurements of the SCM. From the
results in the Table, it can be seen that
lymphocytes from patients with basal
cell carcinoma (BCC) of skin responded
with a decrease in the SCM only when
exposed to the tumour tissue from BCC
of skin and did not respond even to
those of a squamous cell carcinoma
(SCC) of skin. Lymphocytes from pa-
tients with carcinomata of the bladder
responded only to tumour tissue of a
carcinoma of the bladder; they also did
not respond to normal bladder tissue.
Also, lymphocytes from a patient with
carcinoma of renal pelvis responded to
the tissue of the carcinoma of the bladder
and not to that of the carcinoma of the
kidney, possibly indicating the phylogeny
of the renal pelvic tumour. Lympho-
cytes from patients with breast carcino-APPARENT TUMOUR SPECIFITY WITH THE SCM TEST 253
TABLE.-Changes in the SCM ofLymphocytes Induced by Tumour and Normal Tissues
SCM changes as % of control induced by tissues of:
Bone
Diagnosis BCC Ca Normal Ca Ca Ca Ca Fatty t. SCC Ca Ewing's
of blood donors skin bladder bladder kidney breast colon lung lung skin stomach tumour
BCC skin 790 - 106-0 101 0 100-0
BCC skin 78-0 106-0 109 0 100 0
SCC bladder 100-5 79.5 101-0 99-0 100 0
SCC bladder ST3 81-0 96-0 102-0 99-5
Ca renal pelvis 80-0 100-5 109 0 107 0
Ca breast (R) 102-0 106-0 79-5
Ca breast (bone
metastases) 98*0 75 0 98*0 98*0
Ca breast ST2 100.0 74-0 102-0
Ca larynx ST1 101.0 102-0 108-0
SCC bronchus 10190 99 5 80-0 102-0
Ca stomach 100 0 97 5 54.0*
Ca oesophagus 96 0 85-0
Bone Ewing's
tumour 100.0 99.0 74.5
Healthy 98.5 105*0 100.0
Healthy 96e0 101*5 105e0 98e 8
Healthy 100*0 101*0 100.0 98 0
* In this case autologous tissue was used.
mata responded only to the carcinoma
of breast tissue, and lymphocytes from
a patient with squamous cell carcinoma
of bronchus responded only to the car-
cinoma of lung tissue etc. Lymphocytes
from healthy donors did not respond to
any normal or malignant tissue after
up to 60 min incubation.
These preliminary data indicate that
there are tumour tissue specific " anti-
gens " different from CaBP, which lym-
phocytes recognize and respond to with
a decrease in the SCM if brought into
contact or " baited " with tumour cells
similar to those which they have already
encountered in the body of the donor.
Further studies with a variety of tumour
tissues, tumour and normal cell suspen-
sions, as well as those from tissues
affected with inflammatory and other
diseases are in progress.
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